XVIVO Q3 Sales Rise 34% to SEK 252.6M
XVIVO reported Q3 2026 EBITDA of SEK 52.0M, a 21% margin, and EPS of SEK 1.42. The company also received CE certificates for its Heart Assist Transport System.
XVIVO Perfusion AB reported Q3 2026 net sales of SEK 252.6M, a 34% increase YoY. EBITDA was SEK 52.0M, representing a 21% margin, and EPS was SEK 1.42. The company also received CE certificates for its Heart Assist Transport System.